The vital contribution of Impella® before revascularization

A recent study, published on the scientific magazine JACC: Cardiovascular Interventions”, showed how the initiation of early Abiomed Impella® support  before revascularization is associated with a survival benefit among patients with acute myocardial infarction complicated by cardiogenic shock (AMICS).

The meta-analysis includes the results of three researches that compared the use of pre- and post-revascularization support. The outcomes demonstrate that early Impella initiation in AMICS patients reduced 30-day or in-hospital mortality by approximately 48%, a survival benefit that was considered statistically significant (risk ratio: 0.52; 95% confidence interval: 0.31 to 0.88, I2 = 0%; P=0.01). According to the study, the use of Impella® before vascularization provides effective left ventricular unloading and prevents organ hypoperfusion, systemic inflammatory response, and multiorgan dysfunction leading to death of patient.